Nov 23 2009
American International Biotechnology Services™ (AIBioTech™) announces the launch of its Absolute Match™ DNA specimen verification test. The test, which will be performed through AIBioTech’s Fairfax Identity Laboratories™ division, provides absolute confidence for a patient undergoing a biopsy procedure that their specimen and diagnosis is their own.
Erroneous switching of patient specimens is an avoidable problem that can occur at many points throughout the patient’s procedure. Regardless of when or where an error occurs, the potential for patient harm is high, particularly for patients who receive potentially irreversible treatment (or lack thereof) as a result.
Absolute Match, which is highlighted in the special Biotechnology supplement in today’s Wall Street Journal, helps prevent these avoidable errors by using the latest in DNA identity verification technology. A simple cheek swab is collected from the patient and sealed in a tamper-evident bag. The DNA on this swab can then be compared to the DNA from the patient’s biopsy tissue, providing absolute assurance for the patient and physician that no switching error has occurred at any point in the process.
Source:
American International Biotechnology Services (AIBioTech)